Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283292 | 0.87 | SCN9A (0.44) | SCN9ASCN10ASCN7AKCNH2HCRTR2 | |
| SCHEMBL8235660 | 0.83 | LTA4H (0.47) | SCN9ASCN10AGPR119 | |
| SCHEMBL13705101 | 0.83 | GPR119 (0.47) | GPR119MAPK1 | |
| SCHEMBL29913023 | 0.81 | JAK3 (0.41) | SYKGPR119HCRTR2TACR1 | |
| SCHEMBL27158490 | 0.81 | GPR119 (0.51) | SYKGPR119 | |
| SCHEMBL13705108 | 0.81 | IDH1 (0.46) | SCN9ASCN10AGPR119SCN7AKCNH2 | |
| SCHEMBL30328570 | 0.79 | GPR119 (0.48) | SYKGPR119HCRTR2TACR1 | |
| SCHEMBL15645408 | 0.77 | LTA4H (0.44) | GPR119 | |
| SCHEMBL15645409 | 0.77 | LTA4H (0.44) | GPR119 | |
| SCHEMBL13705093 | 0.77 | SCN9A (0.38) | SCN9ASCN10AGPR119MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885SYK 567/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SCN9A 1866/4885SCN10A 2828/4885SYK 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.